Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Turk Ilac ve SerumnayiIST:TRILC +9.42%61 ROC (Joel Greenblatt) % is 58.23% as of Sep. 2025, which is 186% above its 10-year median of 20.36. GuruFocus rates IST:TRILC with a GF Score™ of 61/100 and a GF Value™ of ₺3.63 (Possible Value Trap). The stock has 11 warning signs investors should review. Among 983 Drug Manufacturers companies, Turk Ilac ve Serumnayi ranks better than 72.74% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Turk Ilac ve Serumnayi's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 58.23%.
The historical rank and industry rank for Turk Ilac ve Serumnayi's ROC (Joel Greenblatt) % or its related term are showing as below:
IST:TRILC'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.48 Med: 20.36 Max: 29.24
Current: 28.48
During the past 5 years, Turk Ilac ve Serumnayi's highest ROC (Joel Greenblatt) % was 29.24%. The lowest was 14.48%. And the median was 20.36%.
IST:TRILC's ROC (Joel Greenblatt) % is ranked better than 72.74% of 983
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs IST:TRILC: 28.48
Turk Ilac ve Serumnayi's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -10.20% per year.
Turk Ilac ve Serumnayi (IST:TRILC) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Turk Ilac ve Serumnayi ROC (Joel Greenblatt) % Related Terms
Turk Ilac ve Serumnayi ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Turk Ilac ve Serumnayi's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Turk Ilac ve Serumnayi ROC (Joel Greenblatt) % Chart
IST:TRILC vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Turk Ilac ve Serumnayi's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Turk Ilac ve Serumnayi ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Turk Ilac ve Serumnayi's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Turk Ilac ve Serumnayi's ROC (Joel Greenblatt) % falls into.
Turk Ilac ve Serumnayi ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Sep. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 58.23% mean?
Turk Ilac ve Serumnayi (IST:TRILC) has a ROC (Joel Greenblatt) % of 58.23% as of Sep. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Turk Ilac ve Serumnayi and its competitors. This is 186% above median its historical median of 20.36. Over the past decade, Turk Ilac ve Serumnayi's ROC (Joel Greenblatt) % has ranged from 14.48 to 29.24. According to the industry distribution chart, Turk Ilac ve Serumnayi ranks #268 out of 983 companies in the Drug Manufacturers industry, placing it in the top 27.3%.
Is Turk Ilac ve Serumnayi's ROC (Joel Greenblatt) % too high?
Turk Ilac ve Serumnayi's current ROC (Joel Greenblatt) % of 58.23% is 186% above median its 10-year median of 20.36. Over the past 10 years, this metric has ranged from a low of 14.48 to a high of 29.24. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.46. Turk Ilac ve Serumnayi's value of 58.23% is 408.1% above this industry median. Based on the distribution chart, Turk Ilac ve Serumnayi ranks #268 out of 983 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Turk Ilac ve Serumnayi has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Turk Ilac ve Serumnayi's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Turk Ilac ve Serumnayi ranks #268 out of 983 companies for ROC (Joel Greenblatt) %. This puts Turk Ilac ve Serumnayi in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. Turk Ilac ve Serumnayi's value of 58.23% is 408.1% above this benchmark. Historically, Turk Ilac ve Serumnayi's own ROC (Joel Greenblatt) % has ranged from 14.48 to 29.24 over the past decade. While the company's 10-year median is 20.36 vs. the industry median of 11.46, Turk Ilac ve Serumnayi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Turk Ilac ve Serumnayi's current ROC (Joel Greenblatt) % of 58.23% is 408.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Turk Ilac ve Serumnayi and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Turk Ilac ve Serumnayi's current ROC (Joel Greenblatt) % is 58.23%, which is 186% above median its own 10-year median of 20.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turk Ilac ve Serumnayi stock overvalued right now?
Based on GuruFocus' analysis, Turk Ilac ve Serumnayi (IST:TRILC) is currently considered Possible Value Trap. The stock's GF Value™ is ₺3.63, compared to a current price of ₺1.51 — trading 58.4% below its estimated fair value. The current ROC (Joel Greenblatt) % is 58.23%, which is 186% above median its 10-year median of 20.36 and 408.1% above the Drug Manufacturers industry median of 11.46. Turk Ilac ve Serumnayi's overall GF Score™ is 61/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Turk Ilac ve Serumnayi (IST:TRILC), the current ROC (Joel Greenblatt) % is 58.23% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Turk Ilac ve Serumnayi (IST:TRILC) Overvalued in 2026?
Based on GuruFocus' analysis, Turk Ilac ve Serumnayi stock appears to be undervalued.
The current stock price of ₺1.51 is trading 58.4% below its estimated GF Value™ of ₺3.63.
GuruFocus considers Turk Ilac ve Serumnayi to be Possible Value Trap.
Key valuation signals for IST:TRILC:
ROC (Joel Greenblatt) %: 58.23% (186% above median its 10-year median of 20.36)
GF Value™: ₺3.63 vs. price of ₺1.51 (58.4% below fair value)
Industry Position: 408.1% above the Drug Manufacturers median (#268 of 983)
No single metric tells the full story. See the IST:TRILC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:TRILC has been successfully added to your 
